Can the Tuberculosis Vaccine Reduce the COVID-19 Death Rates?

Oct 29, 2020 | Digital Media, News, TrialSite News, TrialWatch

Beyond the roundup

Can a vaccine that was developed to stop tuberculosis actually inhibit or stop SARS-CoV-2, the virus behind COVID-19? With evidence that the Bacille Calmette-Guérin (“BCG”) vaccine can protect against other viral infections, dozens of studies around the world are investigating this very vaccine as a defense against COVID-19. For example, the UK’s University of Exeter will test this hypothesis on about 1,000 clinical trial volunteers. This UK study is part of the international Brace-study, involving Australia, the Netherlands, Spain and Brazil and involving 10,000 people. TrialSite also reminds us that in the U.S., Texas A&M has a prominent study investigating whether the BCG vaccine can inhibit or stop COVID-19.

0 Comments